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IL-17-mediated M1/M2 Macrophage Alteration Contributes to Pathogenesis of
Bisphosphonate-related Osteonecrosis of the Jaws
Abstract

Purpose
Osteonecrosis of the jaw (ONJ) is emerging as one of the important complications in cancer patients
treated with antiresorptive agents. This study explored the potential role of IL-17-mediated M1/M2
macrophage alterations in the pathogenesis of bisphosphonate-related osteonecrosis of the jaw
(BRONJ).

Experimental Design
The expression of IL-17 and M1 and M2 macrophage markers at the local mucosal site of human BRONJ
lesions was examined by immunofluorescence studies. BRONJ-like disease was induced in C57BL/6
mice and multiple myeloma (MM)-burdened mice by intravenous injection of zoledronate to evaluate the
correlation of elevated IL-17 levels with changes in M1 and M2 macrophage phenotypes and the
therapeutic effects of blocking IL-17 on pathogenesis of BRONJ-like disease.

Results
Increased Th17 cells and IL-17 cytokine correlate with an increase in M1/M2 macrophages ratio at the
local mucosal site of both murine and human BRONJ lesion. Convincingly, in mice burdened with multiple
myeloma, a combination of elevated suprabasal level and drug-induced IL-17 activity augmented the
incidence of BRONJ; both systemic increase of IL-17 and disease severity could be reversed by adoptive
transfer of ex vivo expanded M2 macrophages. Targeting IL-17 via specific neutralizing antibodies or a
small inhibitory molecule, Laquinimod, significantly decreased M1/M2 ratio and concomitantly
suppressed BRONJ-like condition in mice. Mechanistically, IL-17 enhanced IFN-γ-induced M1 polarization
through augmenting STAT-1 phosphorylation while suppressed IL-4-mediated M2 conversion via inhibiting
STAT-6 activation.

Conclusions
These findings have established a compelling linkage between activated IL-17-mediated polarization of
M1 macrophages and the development of BRONJ-like conditions in both human disease and murine
models.

Disciplines
Dentistry

Comments
At the time of publication, author Songtao Shi was affiliated with the University of Southern California, Los
Angeles. Currently, he is a faculty member at the Dental School at the University of Pennsylvania.

Author(s)
Qunzhou Zhang, Ikiru Atsuta, Shiyu Liu, Chider Chen, Shihong Shi, Songtao Shi, and Ahn D. Le

This journal article is available at ScholarlyCommons: https://repository.upenn.edu/dental_papers/319

HHS Public Access
Author manuscript
Author Manuscript

Clin Cancer Res. Author manuscript; available in PMC 2017 August 16.
Published in final edited form as:
Clin Cancer Res. 2013 June 15; 19(12): 3176–3188. doi:10.1158/1078-0432.CCR-13-0042.

IL-17-mediated M1/M2 Macrophage Alteration Contributes to
Pathogenesis of Bisphosphonate-related Osteonecrosis of the
Jaws
Qunzhou Zhang1,#, Ikiru Atsuta2,#, Shiyu Liu2, Chider Chen2, Shihong Shi2, Songtao Shi2,*,
and Anh D Le1,*

Author Manuscript

1Department

of Oral and Maxillofacial Surgery and Pharmacology, University of Pennsylvania
School of Dental Medicine and Penn Medicine Hospital of the University of Pennsylvania,
Philadelphia, Pennsylvania 19104, USA

2Center

for Craniofacial Molecular Biology, The Herman Ostrow School of Dentistry of University
of Southern California, Los Angeles, California 90033, USA

Abstract
Purpose—Osteonecrosis of the jaw (ONJ) is emerging as one of the important complications in
cancer patients treated with antiresorptive agents. This study explored the potential role of IL-17mediated M1/M2 macrophage alterations in the pathogenesis of bisphosphonate-related
osteonecrosis of the jaw (BRONJ).
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Experimental Design—The expression of IL-17 and M1 and M2 macrophage markers at the
local mucosal site of human BRONJ lesions was examined by immunofluorescence studies.
BRONJ-like disease was induced in C57BL/6 mice and multiple myeloma (MM)-burdened mice
by intravenous injection of zoledronate to evaluate the correlation of elevated IL-17 levels with
changes in M1 and M2 macrophage phenotypes and the therapeutic effects of blocking IL-17 on
pathogenesis of BRONJ-like disease.
Results—Increased Th17 cells and IL-17 cytokine correlate with an increase in M1/M2
macrophages ratio at the local mucosal site of both murine and human BRONJ lesion.
Convincingly, in mice burdened with multiple myeloma, a combination of elevated suprabasal
level and drug-induced IL-17 activity augmented the incidence of BRONJ; both systemic increase
of IL-17 and disease severity could be reversed by adoptive transfer of ex vivo expanded M2
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macrophages. Targeting IL-17 via specific neutralizing antibodies or a small inhibitory molecule,
Laquinimod, significantly decreased M1/M2 ratio and concomitantly suppressed BRONJ-like
condition in mice. Mechanistically, IL-17 enhanced IFN-γ-induced M1 polarization through
augmenting STAT-1 phosphorylation while suppressed IL-4-mediated M2 conversion via
inhibiting STAT-6 activation.
Conclusions—These findings have established a compelling linkage between activated IL-17mediated polarization of M1 macrophages and the development of BRONJ-like conditions in both
human disease and murine models.

Introduction

Author Manuscript

Nitrogen containing bisphosphonates (BPs), a widely used anti-bone resorptive agent, has
been associated with osteonecrosis of the jaw (ONJ), a complication of significant impacts
in both medical and dental communities (1, 2). Bisphosphonate related osteonecrosis of the
jaw (BRONJ) is defined as exposed necrotic bone in the oral cavity that does not heal after
appropriate intervention over 8 weeks in the absence of radiation therapy (2, 3). The
incidence of BRONJ in cancer patients receiving high doses of intravenous BP such as
zoledronic acid (ZA) and pamidronate (%) ranged from 0.8~12%, a rate much higher than
that in patients with osteoporosis on oral BP treatment. Among the cancer group, highest
prevalence of bisphosphonate-related osteonecrosis of the jaw (BRONJ) has been reported in
patients with multiple myeloma, followed by breast and prostate cancer (4–7). To date, even
though several risk factors, including invasive dental procedure, infection, mechanical
trauma to the jaw bone, and concomitant use of immunosuppressive and chemotherapy
drugs, have been implicated in the etiology of BRONJ (4, 5), its underlying mechanisms
remains largely unknown.

Author Manuscript
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Macrophages play important role in innate immune response and are an essential component
of the wound healing cascade (8–10). Macrophages can be converted to M1 phenotype upon
stimulation of Th1 cytokines such as interferon (IFN)-γ or lipopolysaccharide (LPS), while
their M2 counterpart, also known as wound healing macrophages, are polarized in response
to Th2 cytokines such as interleukin (IL)-4 or IL-13 (11). M1 macrophages are generally
pro-inflammatory based on their production of nitric oxide (NO), reactive oxygen species
(ROS), interleukin (IL)-12 and tumor necrosis factor (TNF)-α; whereas M2 macrophages
more likely adapt an anti-inflammatory role, characterized by IL-10 and transforming
growth factor (TGF)-β (12–14), contributing to resolution of inflammation and tissue
modeling (15, 16). Given the importance of macrophages in wound healing and the fact that
these cells share similar cell lineage as osteoclasts, it is plausible to hypothesize that
macrophage function may potentially be altered by BP treatment and therefore, contributes
to the defective healing in BRONJ (17). Most recent studies have suggested a potential effect
of zoledronic acid (ZA) in the polarization of tumor associated macrophages (TAMs) in
vitro (18, 19); it remains to be determined comprehensively whether and how the function
and phenotypes (M1 vs M2) of macrophages participate in the pathogenesis of BRONJ.
Interleukin (IL)-17A, a signature cytokine of the T helper cell subset, Th17, has been
indicated in the development of numerous inflammatory, autoimmune diseases, tumors, and
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in host defense against bacterial and fungal infection (20). Besides Th17 cells, γδ T cells
and macrophages are capable to produce IL-17 (21–25). IL-17 can promote recruitment of
macrophage and induce their cytokine/chemokine production, and thus capable of mediating
a link between acquired and innate immunity, specifically, T cell and macrophage functions
(26–30). Most recently, we have demonstrated that administration of zoledronic acid can
induce BRONJ-like lesions in mice, in part by suppressing the adaptive regulatory T cells
(Tregs) and activating the inflammatory Th17 cells (31); this immunomodulatory effect
linking elevated IL-17 and the prolonged inflammatory state associated with delayed wound
healing potentially serve the underlying mechanism of BRONJ-like lesions.

Author Manuscript

In the present study, we first demonstrated an elevated expression of IL-17 in the
inflammatory socket wounds obtained from BRONJ-affected cancer patients with a distinct
histological feature of increased M1 and decreased M2 macrophage infiltration. Using a
BRONJ-like disease murine model, we observed a correlation between an elevated IL-17
level and a combination of increased M1 macrophages and decreased M2 macrophages (an
increased M1/M2 ratio) in both long bone marrow and local necrotic lesions of the jaw bone.
Interestingly, administration of IL-17 neutralizing antibodies or Laquinimod, a small
molecule drug that exhibits inhibitory effects on IL-17 activity (32–34), led to a decrease in
M1/M2 ratio and concomitantly, a reduction in the incidence of BRONJ-like lesion.
Additionally, systemic infusion of ex vivo expanded M2 macrophages significantly
decreased serum IL-17 levels and inhibited BRONJ formation. Mechanistically, we showed
that IL-17 promoted IFN-γ-induced M1 macrophage polarization by enhancing the
phosphorylation of STAT-1; on the other hand, this pro-inflammatory suppressed IL-4induced M2 macrophage conversion through downregulation of STAT-6 phosphorylation.
Therefore, we describe for the first time substantial evidence that IL-17-mediated alteration
of M1/M2 macrophage polarization can contribute to the pathogenesis of BRONJ.

Author Manuscript

Materials and Methods
Animals
C57BL/6J mice (female, 8–10 week-old, Jackson Laboratory), beige nude/nude Xid (III)
(female, 8–10 week-old, Harlan) were used in this study. All animal experiments were
performed under an institutionally approved protocol for the use of animal research at
University of Southern California (USC) (USC #10874, #10941 and #11327).
Patient sample collections

Author Manuscript

The mucosal tissues bordering the extraction sockets were collected from patients
undergoing tooth extraction under different conditions (n=5): 1) BRONJ: patients manifested
BRONJ lesion that were undergoing surgical debridement and tooth extraction for this
condition; 2) Non-BRONJ: patients with history of BP treatment without clinical BRONJ
who underwent tooth extraction for non-restorable indication; 3) Periodontitis: patients with
diagnosis of inflammatory gum disease, specifically, active periodontitis with resultant tooth
loss; and 4) Normal: healthy patients who underwent routine dental extraction for other noninflammatory mucosa condition such as dental crowding indication. The BRONJ group
includes two patients with multiple myeloma, two patients with breast cancer, and one
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patient with osteoporosis treated with IV or oral bisphosphonates, respectively. The study is
approved by the Institutional Review Board (IRB#HS-08-00281) at University of Southern
California.
Reagents and antibodies
Murine and human macrophage colony-stimulating factor (M-CSF), IFN-γ, IL-4, IL-13, and
IL-17 were purchase from PeproTech. Rat PE-conjugated anti-mouse CD11b and FITCconjugated anti-mouse F4/80, mouse PE-conjugated anti-human CD14 and CD68, FITCconjugated anti-human CD206 and CD4 were purchased from BioLegend. Rabbit polyclonal
antibodies for human and mouse iNOS and arginase-1 were from Santa Cruz. A neutralizing
antibody against mouse IL-17A (clone MM17F3) was from eBiosciences.
Lipopolysaccharide (LPS) from Escherichia coli 055:B5, and phorbol 12-myristate 13acetate (PMA) were obtained from Sigma-Aldrich

Author Manuscript

Induction of BRONJ-like lesion in wild type mice and multiple myeloma mouse model
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The BRONJ-like lesions in mice were induced according to the protocol we reported
recently (31). Briefly, wild type C57BL/6 mice or beige nude/nude Xid (III) burdened with
multiple myeloma cells (5TGM) were intravenously injected with zoledronate (Zometa®,
125μg/kg, Novartis Oncology) twice a week via the tail vein. One week after zoledronate
injection, the first maxillary molar teeth were extracted under deep anesthesia by
intraperitoneal injection of ketamine (Ketaject®, 100 mg/kg, Phoenix) and xylazine
(AnaSed®, 20 mg/kg, LLOYD Laboratories Pharmaceutical, Inc.). A total of 6 doses of
zoledronate were administered for 3 consecutive weeks. Untreated mice with tooth
extraction were used as controls. Clinical evaluation of extracted tooth socket and
determination of the incidence of BRONJ-like lesions were done according to the previous
study (31).
Culture of bone marrow-derived macrophages (BMDMs) and adoptive transfer of M1 or M2
macrophages

Author Manuscript

Bone marrow cells were flashed out from mice bone marrow cavity of femurs and tibias
with PBS containing heat-inactivated 3% fetal bovine serum (FBS; Equitech-Bio) and
antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin; Biofluids). All nuclear cells
were seeded at 15 x 106 onto 100 mm culture dishes (Corning) and initially incubated for 3h
under 37°C at 5% CO2 condition. Non-adherent cells were removed by washing the dishes
twice with PBS. The attached cells were continuously cultured in complete DMEM
supplemented with 10% FBS, 100 U/ml penicillin and 100 μg/ml streptomycin, and
10μg/mL murine M-CSF (10ng/mL) for 6 days. Macrophages were incubated for 48h in the
presence of either 20ng/mL IFN-γ or 10ng/mL IL-4 to polarize macrophages into M1 and
M2 macrophages, respectively. M1 macrophages were characterized by the expression of
inducible nitric oxide synthase (iNOS) and secretion of TNF-α in response to LPS
(100ng/mL) stimulation for 24h, while M2 macrophages were characterized by the
expression of arginase-1 and the secretion of IL-10 after stimulation with LPS (100ng/mL)
for 24h (13). One day after tooth extraction, cells were collected and intraperitoneally (i. p.)
administered into mice (1.0 × 106/ mice).
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Treatment of mice with murine IL-17 neutralizing antibody, or Laquinimod during induction
of BRONJ-like lesions
One day after tooth extraction, 0.1mg of mouse monoclonal anti-murine IL-17 neutralizing
antibody (1mg/ml) was intravenously (i. v.) injected into mice twice a week for 2 weeks,
while mice received subclass-matched control antibody (1mg/mouse) served as control. In
addition, one day after tooth extraction, Laquinimod (TEVA Pharmaceuticals Industries,
Ltd), a quinoline-3-Carboxamide, was dissolved in purified water and administered daily (25
mg/kg) by oral gavage for 2 weeks (32–34). Mice without any treatment (control) and only
with tooth extraction served as controls.
Histological and immunohistochemical studies

Author Manuscript

Paraffin-embedded and frozen sections of socket soft tissues from BRONJ patients were
prepared and standard hematoxylin and eosin (H & E) staining and dual-color
immunofluorescence studies using specific primary antibodies for human CD68, iNOS and
arginase-1 were performed. Frozen sections of mice tissues including BRONJ-like lesions,
spleens and long-bone marrows were immunostained with specific antibodies for mice F4/80
and iNOS or arginase-1 to recognize M1 and M2 macrophages as described before (35).
Isotype-matched control antibodies (eBiosciences) were used as negative controls. For semiquantification, positive signals in at least 6 random high-power fields (HPF) were visualized,
counted and expressed as percentage of total DAPI-positive cells (mean ± SD).
Western blot analysis

Author Manuscript

Cell lysates or homogenate tissue lysates (50~100 μg of total protein) were separated on
polyacrylamide-SDS gel and electroblotted onto nitrocellulose membrane (BioRad,
Hercules, CA). After blocking with TBS/5% nonfat dry milk, the membrane was incubated
with antibodies against mouse p-STAT-1 (Tyr701) (Cell Signal), pSTAT-6 (Tyr641)
(Millipore) or arginase-1(Santa Cruz Biotech, Inc.) followed by incubation with a
horseradish peroxidase (HRP)-conjugated secondary antibody, and the signals were
visualized by enhanced chemiluminescence detection (ECL) (PIERCE, Rockford, IL). The
blots were also re-probed with a specific antibody against β-actin (Sigma).
ELISA
The concentration of IL-10, TNF-α and IL-12 (p70) in supernatants of cultured cells was
detected using ELISA kits (BioLegend) according to the manufacturer’s procedures.
Statistical analysis

Author Manuscript

All data are expressed as mean ± SEM from at least three independent experiments.
Differences between experimental and control groups were analyzed by two-tailed unpaired
Student’s t-test using SPSS. P-values less than 0.05 were considered statistically significant.
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Results
Elevated Th17 cell/IL-17 activity and polarized M1 macrophages at the nonhealing
extraction socket of BRONJ patients

Author Manuscript

We have recently reported that intravenous administration of zoledronate, a potent nitrogenbisphosphonate, induces BRONJ-like condition in mice undergoing tooth extraction; this
adverse event is correlated with a decrease in regulatory T cells (Tregs) and a concomitant
increase in Th17 cells and IL-17 production (31). Here, using immunofluorescence staining
of the mucosal tissues bordering the non-healing extraction socket obtained from BRONJ
patients, we confirmed that IL-17 positive cells were dramatically increased at the local
extraction sockets of patients manifested BRONJ lesion that were undergoing surgical
debridement for this condition, as compared to that from control patients without clinical
BRONJ (Fig. 1A and B). The control group included: 1) patients with diagnosis of
inflammatory gum disease, specifically, active periodontitis with resultant tooth loss; and 2)
patients with history of bisphosphonate treatment who did not present with clinical BRONJ
at the time of tooth extraction for non-restorable indication. These IL-17 positive cells were
positive for CD4+ and CD68+, indicating T cell, specifically Th17 subset, and macrophage
lineage, respectively. The elevated IL-17 expression was also confirmed by ELISA using
tissue lysates obtained from the above patient groups (Fig. 1C).

Author Manuscript
Author Manuscript

To investigate the phenotype of macrophage, specifically in the context of wound healing,
we examine the distribution of M1 and M2 macrophages at the BRONJ socket site. A
remarkable infiltration of CD68+ macrophages was noticed in mucosal tissues adjacent to
the extraction sockets of periodontitis affected tooth as compared to clinically healthy tissues
(P<0.01) of patients exposed or not exposed to BP treatment (Fig. 2A–E); likewise, abundant
CD68+ macrophages were also observed in mucosal tissues of BRONJ extraction sockets
relative to those of non-BRONJ (P<0.05) (Fig. 2E). Among the general surge in CD68+
macrophages activity, we noticed a remarkable shift in iNOS-positive (M1) over CD206+
(M2), resulting in an increased M1/M2 ratio, at the non-healing sockets of patients with
history of zoledronate treatment that were diagnosed with or without BRONJ, as compared
to those of periodontitis affected patients that were naïve of zoledronate exposure (P<0.01)
(Fig. 2A–D; Fig. 2F and G). Of note, polarization of M1/M2 ratio was more pronounced at
the mucosal tissue bordering the extraction sockets of BRONJ relative to non-BRONJ
patients (Fig. 2F and G). The abundant activity of M1 macrophages was also confirmed
using a quick cell smear screening approach obtained from the socket of BRONJ patients
(Supplementary Fig. S1). These results suggest that a combination of enhanced IL-17 and
M1/M2 activity may situate the wound environment more of a prolonged inflammatory
state, rendering a generalized delay in the healing of the open extraction socket and
subsequently, osteonecrosis of the jaw.
Systemic IL-17 elevation and a shift to M1 activity render mice vulnerable to osteonecrosis
of the jaw bone, not skeletal bone
To determine whether the enhanced Th17 and IL-17 activity is limited to the local mucosal
tissue bordering the non-healing extraction socket of BRONJ mice, we tested the effect of
elevated serum IL-17 on the development of BRONJ. Here, we performed a series of human

Clin Cancer Res. Author manuscript; available in PMC 2017 August 16.

Zhang et al.

Page 7

Author Manuscript
Author Manuscript

serum transfusion in our murine model using samples collected from BRONJ patients
undergoing surgical debridement versus non-BRONJ patients with history of BP treatment
or healthy controls. We measured serum IL-17 level in BRONJ affected patients, range 100–
200pg/mL (182.5±12.4 pg/mL), in non-BRONJ patients, range ~50pg/mL (58.2±9.8 pg/
mL), as well as in healthy controls, less than 30pg/mL (25.4±6.3pg/mL) (n=5/group)
(Supplementary Fig. S2A). During the course of BP-induction of BRONJ, serum sample
from each patient group was intravenously infused into C57BL/6 mice one day after tooth
extraction and manifestation of BRONJ-like condition was assessed as previously described
(31). Interestingly, we observed development of exposed bone (ONJ) or BRONJ-like
condition in mice that underwent systemic infusion of serum from patients who manifested
active BRONJ, and these ONJ mice showed relatively high serum levels of murine IL-17 and
increased percentage of M1 macrophage or M1/M2 ratio as detected in the long bone
marrow (Supplementary Fig. S2B–E). Despite the seemingly correlation between infused
human serum IL-17 and ONJ incidence in our murine model, we cannot rule out other
factors that potentially contribute to this effect. Further studies are ongoing to address this
finding.
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Since it is well-established that BRONJ occurred predominantly in the jaw bone, we
examined whether there is any difference in IL-17 level in bone marrow derived from jaw
versus long bone. Interestingly, we found a remarkably increase in Th17 cells and IL-17
expression at both mRNA and protein levels in jaw bone marrow as compared to long bone
marrow of C57BL/6 mice, while Treg cells and IL-10 activities were relatively suppressed
(Supplementary Fig. S3A–F); similar trends of increased Th17 and decreased Treg cells
were consistently observed in bone marrow compartment of jaw versus long bone in other
species, C3H mice (Supplementary Fig. S3G–H), and rats (Supplementary Fig. S3I and J).
We next ask whether the differential IL-17 activity affect bone healing at different skeletal
sites. Consistent with previous findings, we showed that IL-17 elevation correlated with high
incidence of exposed bone or ONJ in zoledronate treated wild type C57BL/6 or Bg ZID (III)
nu/nu mice (31) following tooth extraction. However, when subjected nu/nu mice to
surgically induced bone cavitation in the appendicular bone, specifically the tibia, there was
apparently no difference in bone healing between zoledronate treated and non-treated groups
(Supplementary Fig. S4). When evaluating jaw bone healing, residual necrotic alveolar bone
was evident with absolutely no signs of bone filling in the extraction socket of the
zoledronate treated mice (Supplementary Fig. S4A); whereas, in the long bone cavitation
defect, similar callus formation and bone filling was observed in mice that manifested
clinical BRONJ in the jaw bone as compared to nontreated control (Supplementary Fig.
S4B). Taken together, the inherent increase in Th17 activity unique to the jaw bone, the open
tooth extraction wound exposed to the oral microbial environment versus the closed and
sterile wound of the long bone cavitation, and specifically its oral mucosa immunology may
explain the limited manifestation of BRONJ at this bone type.
We further ask whether zoledronate directly affect systemic IL-17 level using our established
model of BRONJ-like disease that showed a high correlation between IL-17 level and
incidence of BRONJ in wild type C57BL/6 mice (31). Consistent with previous findings,
zoledronate treatment augmented serum level of IL-17 (Fig. 3A) over the entire course of
treatment; more importantly, mice that manifested BRONJ-like condition displayed a much
Clin Cancer Res. Author manuscript; available in PMC 2017 August 16.
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higher level of serum IL-17 than those without BRONJ (P<0.01) (Fig. 3B). At the local
mucosa of the non-healing socket, elevated expression of IL-17 mRNA was detected as
confirmed by real-time PCR (Fig. 3C). These results further support the notion that an
elevated IL-17 expression at both systemic and local levels contributes to the development of
BRONJ-like condition.
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It has been suggested that the impaired wound healing characteristic of BRONJ may be
attributed to macrophage dysfunction (17); however, up to date, evidence remains lacking.
Here, using our established BRONJ-like murine model we explore the potential involvement
of macrophages in IL-17-mediated inflammation as a mechanism of impaired healing in
osteonecrosis of the jaw bone. To this purpose, we initially analyzed mRNA expression of
iNOS and arginase-1, a marker for M1 and M2 macrophages, respectively, in mucosal
tissues bordering extraction socket of mice following treatment with zoledronate. As shown
in Fig. 3D–F, an overall elevation of both iNOS and arginase-1 mRNA expression was
detected, with a more remarkable increase in iNOS than arginase-1 (P<0.05), suggesting a
dominance of M1 macrophages in the non-healing extraction socket of BRONJ. To further
confirm this, we examined the local and systemic distribution of M1 and M2 macrophages in
C57BL/6 mice after zoledronate treatment. Using dual-color immunofluorescence staining
of mucosal tissue sections obtained from ONJ sockets we showed a significantly increased
percentage of CD11b+ cells expressing iNOS (M1 macrophages) and a decreased percentage
of CD11b+ cells expressing arginase-1 (M2 macrophages) (P<0.01) (Fig. 3G and H). To
determine whether zoledronate has direct effect on macrophage phenotype switching and
function, we exposed bone marrow-derived macrophages (BMDMs) from BRONJ and nonBRONJ mice under M1 and M2 macrophage induction conditions, respectively. Our results
indicated that a higher percentage of M1 macrophages and a lower percentage of M2
macrophages were induced from BMDMs of zoledronate-treated mice that manifested
BRONJ-like conditions, as compared to those of non-BRONJ mice (P<0.05), or non-treated
mice (P<0.01) (Supplementary Fig. S5A–D). Taken together, these findings support for the
first time, an immune underlying mechanism, linking the elevated IL-17 activity and a shift
in M1/M2 macrophage ratio to the development of BRONJ-like condition in the murine
model.
Blocking IL-17 activity negates M1/M2 macrophage polarization and the incidence of
BRONJ-like condition in mice burdened with multiple myeloma (MM)
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Recent studies have reported a significantly elevated baseline and induced frequency of
Th17 cells in peripheral blood mononuclear cells (PBMCs) and an increased serum IL-17
levels in multiple myeloma (MM) patients (36), implying a critical role of Th17 cells in the
genesis of MM bone lytic diseases (37). Additionally, it has been well-documented that the
highest prevalence of BRONJ occurs in MM patients receiving zoledronate treatment (4, 5).
To test the potential contribution of IL-17 in the pathogenesis of BRONJ in MM, we induced
BRONJ-like condition in a well-established MM murine model (Fig. 4A–C) adapting the
protocol used in wild type C57BL/6 mice as previously published (31). Manifestation of
BRONJ-like phenotype followed tooth extraction was confirmed by clinical examination
(Fig. 4B). Overall, MM mice displayed a significantly elevated basal level of serum IL-17 as
compared to wild type C57BL/6 mice (Fig. 4D vs Fig. 3B), and zoledronate treatment
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further augmented serum IL-17 levels above the baseline (P<0.05). Consistent with the
incidence of BRONJ in zoledronate induced wild type C57BL/6 (31), in MM mice we
observed a baseline disease of 20% (Fig. 4C), which correlated with similar serum IL-17
level in both disease models (Fig. 3B; Fig. 4D). Intravenous administration of zoledronate
into MM mice caused a remarkably higher incidence of BRONJ (~80%) as compared to
wild type C57BL/6 mice (Fig. 4B and C). The 2–3 fold increase in ONJ incidence in druginduced MM mice corresponded to the augmented serum IL-17 level (Fig. 4D); furthermore,
consistent with previous findings in wild type mice, we observed an increased M1 and a
decreased M2 macrophage activity, specifically a significant shift in M1/M2 ratio, in mucosa
of MM mice sustained BRONJ-like condition (P<0.05) (Fig. 4E and F).
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To further explore the critical role of IL-17 and altered M1/M2 macrophage balance in the
development of BRONJ-like condition, we tested several therapeutic approaches modifying
macrophage function or targeting IL-17 using: 1) adoptive transfer of ex vivo expanded M1
and M2 macrophages; 2) treatment with a popular small molecule inhibitor of IL-17 activity
(Laquinimod); and 3) treatment with a specific IL-17 neutralizing antibody (Fig. 5A). We
showed that adoptive transfer of M1 macrophages had no obvious effect on serum IL-17
levels and BRONJ incidence (data not shown); on the contrary, infusion of M2 macrophages
significantly suppressed the incidence of BRONJ in MM mice (Fig. 5B–D) and serum levels
of IL-17 (Fig. 5E). In addition, we demonstrated that oral administration of Laquinimod
reduced the incidence of BRONJ (Fig. 5B–D), and simultaneously led to a decrease in serum
IL-17 levels (Fig. 5E) and M1/M2 macrophage ratio in long bone marrow of MM mice (Fig.
5F and G). Convincingly, administration of IL-17 neutralizing antibody led to a remarkable
decrease in M1/M2 ratio in long bone marrow (Fig. 5F and G), and concomitantly, a
significant reduction in the incidence of BRONJ in MM mice (Fig. 5B–D). Taken together,
these results have provided substantial evidence that an elevated IL-17 level and a shift in
M1/M2 macrophage polarization contribute to the delayed healing in zoledronate induced
osteonecrosis of the extracted socket in murine jaw bone.
Potential mechanisms underlying IL-17-mediated alterations in the phenotype and function
of M1/M2 macrophages
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We next explored the effects of IL-17 on polarization of M1/M2 macrophages in vitro and
their potential mechanisms. To this end, BMDMs from C57BL/6 mice or human
macrophages (THP-1) were cultured under M2 macrophage induction condition in the
presence or absence of IL-17 for 48 hours. Exposure to exogenous IL-17 enhanced murine
and human M1 macrophage polarization as represented by an increased secretion of proinflammatory cytokines TNF-α and IL-12 (P<0.05) (Fig. 6A and B). Since INF-γ-mediated
STAT-1 signaling pathway plays a central role in polarization of M1 macrophages (38), we
then examined whether exogenous IL-17 has any effect on INF-γ-mediated activation of
STAT-1. We showed that IFNγ induced phosphorylation of STAT-1 (Tyr701) at 2h and 4h
time intervals, and even a more pronounced induction of p-STAT1 was noticed at 12h and
24h after IFNγ stimulation (Fig. 6C). Semi-quantitative analysis showed that addition of
IL-17 enhanced IFNγ-induced phosphorylation of STAT-1 by about 2-fold at 4h, and by
about 1.5-fold at 12 and 24h, respectively (Supplementary Fig. S6). These results suggest
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that IL-17 promotes M1 macrophage polarization possibly by enhancing INF-γ-mediated
activation of STAT-1 signaling pathway.
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We then examined the effects of exogenous IL-17 on M2 macrophage polarization and its
underlying mechanism. Using a series of studies with BMDMs from C57BL/6 mice or
human macrophages (THP-1), we applied M2 macrophage polarization condition in the
absence or presence of IL-17. Our results showed that pretreatment with IL-17 dramatically
inhibited murine and human M2 macrophage polarization as represented by a reduced
secretion of the anti-inflammatory cytokine IL-10 (Fig. 6D and E) and a decreased
expression of arginase-1in mice BMDMs (Fig. 6F), a specific marker for M2 macrophages.
We next examined the effects of exogenous IL-17 on IL-4-mediated STAT-6 signaling
pathway in the polarization of M2 macrophages. The data indicated that pretreatment with
IL-17 significantly suppressed the phosphorylation of STAT-6 in mice BMDMs stimulated
by IL-4 (Fig. 6G), suggesting that IL-17 inhibited M2 macrophage polarization by directly
suppressing IL-4-mediated activation of STAT-6 signaling pathway. Further in-depth studies
are underway to delineate the underlying mechanism of IL-17-mediated activation of
STAT-1/STAT-6 balance and how they contribute to M1 and M2 switching in delayed
healing in drug-induced osteonecrosis of the jaw bone.

Discussion
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Over the last decade, osteonecrosis of the jaw (ONJ) has emerged as a devastating and
debilitating condition of oncological patients receiving treatment with high doses of antiresorptive agents (bisphosphonates and denosumab) (39). Epidemiological data from the
latest cohort studies indicate that 88% of the 2408 ONJ cases were associated with
intravenous therapy primarily with zoledronate alone, or zoledronate sequentially with
pamidronate, while only 261 cases (11%) had ever received oral BP treatment. Among these
ONJ cases, the majority of them (89%) were oncological patients, with multiple myeloma
accounting for 43%, breast cancer for 32%, prostate cancer for 9% and other cancers for 5%
(40). To date, several thousands of ONJ cases have been reported in the literature; however,
the pathophysiology or etiology of this condition remains largely unknown. Even though
several potential mechanisms have been implicated in the pathophysiology of
bisphosphonate-related osteonecrosis of jaw (BRONJ), including over-suppressed alveolar
bone turnover, toxicity to oral mucosal tissues, altered angiogenesis and deregulated immune
functions that are directly or indirectly caused by BP therapy (17, 39), none of them can
delineate the full spectrum of the pathophysiology of BRONJ. Conceivably, both
epidemiological/retrospective and clinical prospective studies have identified several major
risk factors for BRONJ including the type, the route and the cumulative dose of BPs,
preexisting infection, oral trauma/injury such as dentures and tooth extraction, the presence
of metastases and obesity, and other medical morbidity conditions (17, 39). In spite of these
factors identified so far that are related to BRONJ prevalence, no direct causal effects have
been established due to the lack of evidence-based studies and a well-accepted BRONJ-like
animal model that can recapitulate the major pathophysiological characteristics of BRONJ in
patients.
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Most recently, we have established a BRONJ-like model in mice by intravenous
administration of zoledronate in conjunction with the addition of immunosuppressive agent
dexamethasone preceding tooth extraction, which displayed similar hallmarks of human
diseases including the persistent presence of BRONJ-like clinical, radiographic and
histologic features at the extraction site (31). More importantly, we showed that the BRONJlike condition was closely associated with an altered immune homeostasis, specifically a
deficiency in Tregs and a significant increase in Th17 cells and IL-17 level in peripheral
blood, which might contribute to the prolonged inflammation at the local extraction sites
(31). In the present study, an elevated IL-17 expression was also observed in the serum and
local mucosal tissues bordering the non-healing extraction socket of BRONJ patients (Fig.1;
Supplementary Fig. 2A). We further showed that an elevated serum level of IL-17 was
tightly correlated to an increased incidence of BRONJ-like conditions in wild type C57BL/6
mice (Fig. 3) and MM mice (Fig. 4). Moreover, blocking IL-17 activity using specific
neutralizing antibody significantly reduced the incidence rate of BRONJ in MM mice (Fig.
5), thus further confirmed the essential role of IL-17 in the pathogenesis of this condition.
These findings further support the notion that an elevated IL-17 level may serve as a major
risk factor in patients sustaining BRONJ. Consistent with our findings in both murine model
and human BRONJ disease, a recent study reported that MM patients experienced an
elevated serum level of IL-17 and other related pro-inflammatory cytokines, including IL-21,
IL-22 and IL-23 (36). However, an earlier short letter described decreased serum IL-17
levels in MM patients following administration of bisphosphonates and those presented with
ONJ as compared to non-treated MM or MM patients without ONJ (41). This seemingly
controversial observation needs to be addressed in light of the well-recognized immunestimulatory effect of the aminophosphates and related compounds (42, 43). Clinical studies
by our group using increased sample size for ONJ and non-ONJ patients in oncologic
patients with MM or other type of cancers are in progress to further confirm the changes in
IL-17 levels both locally and systemically, and to determine whether these levels correlate
with ONJ phenotypes.
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As a potent pro-inflammatory cytokine, IL-17 is principally produced by a subset of CD4+ T
helper (Th17) cells, but recent evidence has shown that it can also be produced by innate
immune cells, including γδ T cells, macrophages and mast cells under certain
pathophysiological settings (21–25). Accumulating evidence has shown that IL-17-mediated
inflammation is crucial to the pathogenesis of several inflammatory and autoimmune
diseases including rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus
erythematosus (SLE), inflammatory bowel disease (IBD) and psoriasis (20). Most recently,
several lines of evidence have demonstrated the important role of IL-17-mediated
inflammation in bone loss or destruction-related diseases (37, 44–46). IL-17 drives
irreversible bone loss or destruction by directly promoting osteoclastogenesis (37, 47) and/or
by interplaying with other pro-inflammatory cytokines like TNF-α to enhance the
expression of several important inflammatory mediators (48). In addition, the interplay
between IL-17 and macrophages may exaggerate IL-17-mediated inflammatory responses.
On one aspect, classically activated or M1 macrophages can produce cytokines such as IL-6
and IL-23 that are essential for Th17 differentiation (11, 20); on the other aspect, IL-17 can
promote the recruitment and pro-inflammatory cytokine/chemokine production of
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macrophages (26–30), suggesting a potential role of IL-17 in the induction of M1
macrophages. Under certain conditions, secretion of IL-17 by macrophages in response to
pro-inflammatory or allergic stimuli can play a major role in the inflammatory process (22,
23). In this study, we have provided the first line of evidence that an elevated IL-17
expression was closely correlated with an increased M1/M2 macrophage ratio at the local
mucosal tissue of non-healing extraction socket of BRONJ patients, whereby the elevated
IL-17 level at the local sites was shown to be attributed to both Th17 cells and macrophages
(Fig. 1; Fig. 2). Using mice BRONJ-like disease model, we have shown that an elevated
IL-17 production in mice with BRONJ is closely associated with a significant increase in the
percentage of M1 macrophages and a decrease in M2 macrophages, which is represented as
an increased M1/M2 ratio (Fig. 3; Supplementary Fig. S5); moreover, blocking of IL-17
activity by using a neutralizing antibody or small immunosuppressive molecule such as
Laquinimod reversed the alteration in M1/M2 macrophages ratio and concomitantly reduced
the incidence of BRONJ in mice (Fig. 5). Convincingly, adoptive transfer of M2
macrophages led to a remarkable decrease in serum levels of IL-17 and a corresponding
reduction in the incidence of BRONJ in MM mice (Fig. 5). In vitro studies further showed
that exogenous IL-17 promoted M1 macrophage polarization via augmenting IFN-γmediated activation of STAT-1 signaling pathway, and inhibited M2 macrophage
polarization by interfering IL-4-mediated activation of STAT-6 signaling pathway (Fig. 6).
These findings have provided compelling evidence that IL-17-mediated alterations in
M1/M2 macrophages contribute a crucial role in the pathophysiology of BRONJ-like
disease.
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Zoledronic acid and other BPs are capable of suppressing bone loss via inhibition of
osteoclast activity (1–3). Several evidences describe the close interplay between Th17 cells
and M1 macrophages (11, 20; 26–30); it remains largely unknown whether these
interactions participate in zoledronate mediated IL-17 increase. Recent studies have
demonstrated that suppressor of cytokine signaling-3 (SOCS3) can repress the
proinflammatory M1 macrophage phenotype, whereas SOCS3 deficiency promotes M1
macrophage polarization and inflammation via an increased production of proinflammatory
cytokines IL-1β, IL-6, IL-12 and IL23, rendering a microenvironment conditioned for the
differentiation of Th1 and Th17 cells (49, 50). Interestingly, zoledronic acid has been shown
to induce M2-like tumor associated macrophages (TAMs) toward an M1 phenotype (51) and
enhances proinflammatory cytokine production through inhibition of SOCS3 expression in
macrophages (19). These findings could explain the mechanisms whereby zoledronic acid
drives Th17 differentiation, at least in part, through promoting M1-macrophage polarization
and activation (18). Based on these studies and our current findings, we postulate a positive
feedback loop between zoledronate-induced IL-17 elevation and M1/ M2 macrophages
switch, regulated in part via STAT-1/STAT-6 activation, as an underlying mechanism in
BRONJ pathogenesis (Supplementary Fig. S7). However, it is noteworthy that microbial
flora and its biofilm, a common feature of ONJ (52), can also affect differentiation and
function of both macrophages and Th17 cells. Further in-depth studies are required to
delineate how zoledronic acid and the oral microbial flora can dependently and/or
independently modulate the complex network among Th17, M1/M2 macrophages and other
types of immune cells in ONJ. In addition to zoledronate, recent clinical trials have reported
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that patients treated with denosumab, a monoclonal antibody against human receptor
activator of NFκB ligand (RANKL) popularly prescribed as an anti-resorptive drug in
osteoporosis and certain cancer patients, experienced similar incidence of ONJ (39, 53). The
fundamental question whether denosumab induced ONJ shares similar pathways as that of
BP-related ONJ, particularly their effects on the interplays between Th17 cells and M1/M2
macrophages, remains to be determined.
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A growing body of evidence has shown that activation M1 macrophage within tumor
microenvironment can boost inflammatory reaction as a mechanism for immune surveillance
of cancer cells. This same mechanism is contributory to the prolonged inflammatory state
associated with delayed wound healing, as observed in the refractory soft tissue collected
from BRONJ site in human studies (Fig. 2). The tumor associated macrophages (TAMs)
with similar characteristics of M2 macrophages can suppress immune response and promote
angiogenesis and metastasis of tumor cells, thus facilitating cancer progression, or
attenuating inflammation and enhancing wound healing (54). Recently, both in vitro and in
vivo studies have shown that tumor macrophages are potential targets of BPs (18, 19, 51),
possibly via the manipulation of macrophage phenotypes in tumor microenvironment, and
by similar mechanisms, sustain prolonged inflammation leading to an increased
susceptibility to BRONJ. Epidemiologic study has identified several risk factors associated
with ONJ; in cancer patients receiving high-dose intravenous BPs for the prevention and
treatment of skeletal-related complications, treatment with other anti-tumor drugs including
glucocorticoid (dexamethasone), chemotherapeutic or/and anti-angiogenic drugs incur
additional risks; as such, it should be further explored whether BPs and these anti-tumor
drugs have any cooperative effects on the immune system, specifically on the interplay
between Th17 cells and M1/M2 macrophages, as these immune cells potentially function as
a “double-edge” sword within the tumor microenvironment to enhance both anti-tumor
immunity and inflammatory responses (18, 39). Such mechanisms inadvertently result in
prolonged inflammation, and thus delayed healing or bone necrosis manifested as BRONJ.
In summary, we have demonstrated for the first time to our knowledge that a combination of
elevated IL-17 activity and a shift in M1/M2 macrophages ratio, contributes to the
pathophysiology of BRONJ-like condition in both human and murine models. Blocking
IL-17/M1 macrophage axis using small molecules or neutralizing antibodies can offer novel
therapeutic modality for preventing and treating BRONJ condition in the vulnerable cancer
patients.
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Translational Relevance
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Osteonecrosis of the jaw (ONJ) is emerging as one of the important complications in
cancer patients with metastatic bone disease treated with antiresorptive agents. This work
reports that increased Th17 cells and IL-17 cytokine levels correlate with an increase in
M1/M2 macrophages ratio at the local mucosal site of both BRONJ patients and
zoledronate-induced ONJ-like lesions in mice; adoptive transfer of ex vivo expanded M2
macrophages could reverse systemic increase of IL-17 and ONJ severity and blocking
IL-17 activity significantly decreased M1/M2 ratio and concomitantly suppressed
BRONJ-like condition in mice. IL-17-mediated inflammation related to M1/M2
macrophage alterations induced by zoledronate may be beneficial for cancer therapy, but
also contributes to an increased susceptibility to BRONJ. These results suggest that it
would be critical to establish optimal approaches for zoledronate administration that can
balance its dual effects on cancer therapy and BRONJ development.
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Increased expression of IL-17 in oral mucosal tissues bordering the non-healing extraction
socket of BRONJ patients. A and B, Immunofluorescence studies showed increased
expression of IL-17 in both CD4+ T cells and CD68+ macrophages in mucosal tissues
bordering the extraction sockets of patients manifested BRONJ lesions (BRONJ) or patients
with history of zoledronate treatment without clinical BRONJ (Non-BRONJ) (n=5),
whereby oral mucosal tissues from healthy patients who underwent routine dental extraction
for other non-inflammatory mucosa conditions (Normal) or healthy patients with diagnosis
of inflammatory gum disease, specifically, active periodontitis with resultant tooth loss
(Periodontitis) were used as controls (n=5). Scale bars, 50μm. C, IL-17 levels in the tissue
lysates were examined by ELISA. Data are mean ± SEM of multiple fields in n=5 per group.
*P < 0.05; **P<0.01.
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Figure 2.
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Altered M1 and M2 macrophage infiltrations in oral mucosal tissues bordering the nonhealing extraction socket of BRONJ patients. A–D, Immunofluorescence studies showed an
increased infiltration of CD68+ iNOS+ M1 macrophages and a decreased infiltration of
CD206+ M2 macrophages in mucosal tissues bordering the extraction sockets of patients
manifested BRONJ lesions (BRONJ) or patients with history of zoledronate treatment
without clinical BRONJ (Non-BRONJ) (n=5), whereby oral mucosal tissues from healthy
patients who underwent routine dental extraction for other non-inflammatory mucosa
conditions (Normal) or patients with diagnosis of inflammatory gum disease, specifically,
active periodontitis with resultant tooth loss (Periodontitis) were used as controls (n=5).
Scale bars, 50μm. E, Quantification of total CD68+ macrophages in 6 randomly selected
high-power fields (HPFs). F and G, Quantification of M1 and M2 macrophages in 6
randomly selected high-power fields (HPFs). Data are mean ± SEM of multiple fields in n=5
per group. *P < 0.05; **P<0.01; ns, no significant statistical differences.
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Figure 3.
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An elevated IL-17 level was correlated with altered M1 and M2 macrophage phenotypes in
mucosal tissues bordering extraction socket of C57BL/6 mice with BRONJ-like lesions.
Mice were intravenously given one dose of zoledronate (Zol) (125μg/kg) one week before
tooth extraction followed by intravenous injection of Zol twice a week for two weeks. A,
Dynamic changes in serum IL-17 levels of C57BL/6 mice within one week after tooth
extraction. Data represent mean ± SEM (n=5 per group). **P<0.01. B, An elevated serum
IL17 level was correlated with BRONJ-like lesion development. Ext (−), normal mice
without tooth extraction; Ext control, mice with tooth extraction but without Zol treatment;
Zol(+)BRONJ(−), mice with tooth extraction and Zol treatment but without BRONJ-like
lesion development; Zol(+)BRONJ(+), mice with tooth extraction and Zol treatment
developed BRONJ-like lesions. Data represent mean ± SEM (n=5 per group). *P<0.05,
**P<0.01 as compared with Ext control. $$P < 0.01 as compared with Zol (+) BRONJ (−).
C–F, Real-time PCR analysis showed increased expression of IL-17, iNOS mRNA but
decreased expression of arginase-1 mRNA in soft socket tissues of Zol(+)BRONJ(+) mice as
compared with those of Zol(+)BRONJ(−) mice. Data represent mean ± SEM (n=5 per
group). *P<0.05, **P<0.01 as compared with Ext (+) control. $P < 0.05, $$P < 0.01 as
compared with Zol (+) BRONJ (−). G and H, Immunofluorescence studies showed an
increased number of CD11b+ iNOS+ M1 macrophages and a decreased number of CD11b+
Arginase-1+ (Arg-1) M2 macrophages (an increased M1/M2 ratio) in mucosal tissues
Clin Cancer Res. Author manuscript; available in PMC 2017 August 16.
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bordering socket tissues of Zol(+)BRONJ(+) mice as compared with those of
Zol(+)BRONJ(−) mice. Scale bars, 100 μm. Data represent mean ± SEM quantification of
M1/M2 macrophages (multiple images, n=3 per group). **P<0.01 as compared with Ext
control. $P < 0.05, $$P < 0.01 as compared with Zol (+) BRONJ (−).
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An elevated IL-17 level was correlated with altered M1 and M2 macrophage phenotypes in
mucosal tissues bordering extraction sockets of multiple myeloma (MM)-burdened mice
with BRONJ-like lesions. A, Treatment regimen. Mice were intravenously given one dose of
zoledronate (Zol) (125μg/kg) one week before tooth extraction followed by intravenous
injection of Zol twice a week for two weeks. B and C, Induction of BRONJ-like lesions in
MM mice. Data represent mean ± SD (n=10 per group). **P<0.01 as compared with Ext
control (C). D, An elevated serum IL-17 level in Zol(+) BRONJ(+) mice as compared with
that of Zol(+)BRONJ(−) mice. Data represent mean ± SEM (n=5 per group). *P<0.05 as
compared with Ext (+) control; $P < 0.05 as compared with Zol (+) BRONJ (−). E and F, An
increased number of CD11b+ iNOS+ M1 macrophages and a decreased number of CD11b+
Arginase-1+ M2 macrophages in mucosal tissues bordering extract sockets of Zol(+)
BRONJ(+) MM mice as compared with that of Zol(+) BRONJ(−) MM mice as determined
by immunofluorescence studies. Data represent mean ± SEM quantification of M1/M2
macrophages in mucosal tissues of BRONJ-like lesions of mice (multiple images n=3 per
group). #P<0.01 as compared with C57BL/6 mice (B6); *P<0.05, **P<0.01 as compared
with Ext control; $P < 0.05, $P < 0.01 as compared with Zol (+) BRONJ (−). Ext (−), normal
mice without tooth extraction; Ext control, mice with tooth extraction but without Zol
treatment; Zol(+)BRONJ(−), mice with tooth extraction and Zol treatment but without
manifestation of BRONJ-like lesions; Zol(+)BRONJ(+), mice with tooth extraction and Zol
treatment developed BRONJ-like lesions.
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Systemic infusion of M2 macrophages and blocking IL-17 activity suppress BRONJ-like
lesion formation in MM mice. A, Treatment regimen. Mice were intravenously given one
dose of zoledronate (Zol) (125μg/kg) one week before tooth extraction followed by
intravenous injection of Zol twice a week for two weeks. One day after tooth extraction,
mice were adoptively transferred with ex vivo expanded M2 macrophages (1x106) or
administered with laquinimod (Laq; 5mg/kg) or IL-17 neutralizing antibody (@IL-17,
0.3mg/mice). B–D, Amelioration of BRONJ-like lesion formation by adoptive transfer of ex
vivo expanded M2 macrophages, daily oral administration of Laq or intraperitoneal (i.p.)
administration of murine neutralizing @IL-17 one day after tooth extraction. Data represent
mean ± SEM (n=10 per group). **P<0.01 as compared with Ext control; &P < 0.05
and &&P<0.01 as compared with Zol (+). E, A reduction in serum IL-17 level after adoptive
transfer of ex vivo expanded M2 macrophages, daily oral administration of Laq or
intraperitoneal (i.p.) administration of murine neutralizing @IL-17 one day after tooth
extraction. Data represent mean ± SEM (n=5 per group). ##P<0.01 as compared with
C57BL/6 mice (B6); **P<0.01 as compared with Ext control; &P < 0.05 and &&P<0.01 as
compared with Zol (+). F and G, A decrease in M1/M2 ratio in mucosal tissues bordering
extraction sockets of mice after adoptive transfer of ex vivo expanded M2 macrophages,
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daily oral administration of Laq or intraperitoneal (i. p.) administration of murine
neutralizing @IL-17 one day after tooth extraction. Data represent mean ± SEM of
quantification of M1/M2 macrophages in BRONJ-like lesions of mice (multiple images, n=3
per group). #P<0.05 and ##P<0.01 as compared with C57BL/6 mice (B6); $P<0.05 as
compared with Ext control; *P<0.05 and **P<0.01 as compared with Zol (+) BRONJ
(−); &P < 0.05 and &&P<0.01 as compared with Zol(+)BRONJ(+).
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Mechanisms underlying IL-17-mediated alterations of M1 and M2 macrophage phenotypes.
Mice bone marrow-derived monocytes were cultured in the presence of M-CSF (10ng/mL)
for 6 days to induce differentiation of mice bone marrow-derived macrophages (BMDMs),
while human leukemic monocytes (THP-1) were differentiated into macrophages in the
presence of PMA (200 nmol/L) for 24 hours. A and B, Mice BMDMs or human
macrophages were continuously cultured under M1 macrophage polarization condition
(IFN-γ, 20ng/mL) in the presence or absence of murine or human IL-17 (10ng/mL) for
another 24 hours. The production of murine or human TNF-α in the supernatants was
determined by ELISA. C, Mice BMDMs were continuously cultured under M1 macrophage
polarization condition (IFN-γ, 20ng/mL) in the presence or absence of murine IL-17
(10ng/mL) for different time periods, and the phosphorylated levels of STAT-1 were
determined by Western blot. D and E, Mice BMDMs or human macrophages were
continuously cultured under M2 macrophage polarization condition (IL-4 10ng/mL) in the
presence or absence of murine or human IL-17 (10ng/mL) for another 24 hours, and the
production of murine or human IL-10 in the supernatants were determined by ELISA. F,
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Mice BMDMs were continuously cultured under M2 macrophage polarization condition
(IL-4 10ng/mL) in the presence or absence of murine IL-17 (10ng/mL) for another 24 hours,
and the expression of arginase-1 (Arg-1) was determined by Western blot analysis. G, Mice
BMDMs were continuously cultured under M2 macrophage polarization condition (IL-4
10ng/mL) in the presence or absence of murine IL-17 (10ng/mL) for another 2 hours, and
the phosphorylated levels of STAT-6 were determined by Western blot analysis. Data
represent mean ± SEM of three independent experiments. *P < 0.05; **P<0.01.
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